<article xmlns="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle http://dtd.nlm.nih.gov/2.0/xsd/archivearticle.xsd" article-type="brief-report">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Cell Host Microbe</journal-id>
      <journal-title-group>
        <journal-title>Cell Host &amp; Microbe</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1931-3128</issn>
      <issn pub-type="epub">1934-6069</issn>
      <publisher>
        <publisher-name>Cell Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3098964</article-id>
      <article-id pub-id-type="pmid">21575914</article-id>
      <article-id pub-id-type="publisher-id">CHOM566</article-id>
      <article-id pub-id-type="doi">10.1016/j.chom.2011.04.005</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Short Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Restoration of Pattern Recognition Receptor Costimulation to Treat Chromoblastomycosis, a Chronic Fungal Infection of the Skin</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>da Glória Sousa</surname>
            <given-names>Maria</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Reid</surname>
            <given-names>Delyth M.</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schweighoffer</surname>
            <given-names>Edina</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tybulewicz</surname>
            <given-names>Victor</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ruland</surname>
            <given-names>Jürgen</given-names>
          </name>
          <xref rid="aff3" ref-type="aff">3</xref>
          <xref rid="aff4" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Langhorne</surname>
            <given-names>Jean</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yamasaki</surname>
            <given-names>Sho</given-names>
          </name>
          <xref rid="aff5" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Taylor</surname>
            <given-names>Philip R.</given-names>
          </name>
          <xref rid="aff6" ref-type="aff">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Almeida</surname>
            <given-names>Sandro R.</given-names>
          </name>
          <xref rid="aff7" ref-type="aff">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brown</surname>
            <given-names>Gordon D.</given-names>
          </name>
          <email>gordon.brown@abdn.ac.uk</email>
          <xref rid="aff1" ref-type="aff">1</xref>
          <xref rid="cor1" ref-type="corresp">∗</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Aberdeen Fungal Group, Section of Immunology and Infection, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK</aff>
      <aff id="aff2"><label>2</label>National Institute for Medical Research, London NW7 1AA, UK</aff>
      <aff id="aff3"><label>3</label>Institut für Molekulare Immunologie, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany</aff>
      <aff id="aff4"><label>4</label>Laboratory of Signaling in the Immune System, Helmholtz Zentrum München - German Research Center for Environmental Health, 85764 Neuherberg, Germany</aff>
      <aff id="aff5"><label>5</label>Division of Molecular Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan</aff>
      <aff id="aff6"><label>6</label>Department of Infection, Immunity, and Biochemistry, School of Medicine, Cardiff University, Cardiff CF14 4XN, Wales, UK</aff>
      <aff id="aff7"><label>7</label>Departamento de Análises Clínicas e Toxicológicas, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo 05508-900, Brazil</aff>
      <author-notes>
        <corresp id="cor1"><label>∗</label>Corresponding author <email>gordon.brown@abdn.ac.uk</email></corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>19</day>
        <month>5</month>
        <year>2011</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
      <pub-date pub-type="ppub">
        <day>19</day>
        <month>5</month>
        <year>2011</year>
      </pub-date>
      <volume>9</volume>
      <issue>5</issue>
      <fpage>436</fpage>
      <lpage>443</lpage>
      <history>
        <date date-type="received">
          <day>10</day>
          <month>12</month>
          <year>2010</year>
        </date>
        <date date-type="rev-recd">
          <day>28</day>
          <month>2</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>8</day>
          <month>4</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2011 Elsevier Inc.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <copyright-holder>Elsevier Inc.</copyright-holder>
        <license>
          <license-p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>Summary</title>
        <p>Chromoblastomycosis is a chronic skin infection caused by the fungus <italic>Fonsecaea pedrosoi</italic>. Exploring the reasons underlying the chronic nature of <italic>F. pedrosoi</italic> infection in a murine model of chromoblastomycosis, we find that chronicity develops due to a lack of pattern recognition receptor (PRR) costimulation. <italic>F. pedrosoi</italic> was recognized primarily by C-type lectin receptors (CLRs), but not by Toll-like receptors (TLRs), which resulted in the defective induction of proinflammatory cytokines. Inflammatory responses to <italic>F. pedrosoi</italic> could be reinstated by TLR costimulation, but also required the CLR Mincle and signaling via the Syk/CARD9 pathway. Importantly, exogenously administering TLR ligands helped clear <italic>F. pedrosoi</italic> infection in vivo. These results demonstrate how a failure in innate recognition can result in chronic infection, highlight the importance of coordinated PRR signaling, and provide proof of the principle that exogenously applied PRR agonists can be used therapeutically.</p>
      </abstract>
      <abstract abstract-type="graphical">
        <sec>
          <title>Graphical Abstract</title>
          <p>
            <fig id="dfig1" position="anchor">
              <graphic xlink:href="fx1"/>
            </fig>
          </p>
        </sec>
        <sec>
          <title>Highlights</title>
          <p>► <italic>F. pedrosoi</italic> is recognized by C-type lectins, but not by Toll-like receptors ► Inflammatory responses to <italic>F. pedrosoi</italic> are defective, which leads to chronic infection ► Exogenous TLR costimulation restores inflammatory responses and clears infection</p>
        </sec>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec id="sec1">
      <title>Introduction</title>
      <p>Chromoblastomycosis is a chronic nonfatal mycosis involving the skin and subcutaneous tissues, which is caused by a number of melanized fungi. The disease occurs worldwide, but is observed most frequently in tropical and subtropical regions of Africa and Latin America (<xref rid="bib1 bib21" ref-type="bibr">Ameen, 2009; Santos et al., 2007</xref>). Infection is acquired by the accidental inoculation of the etiologic agent into the subcutaneous tissues, but it usually takes decades following inoculation before clinical symptoms develop. The infection is characterized by erythematous papules, which develop with varying morphology, and systemic invasion is rare (<xref rid="bib1 bib21" ref-type="bibr">Ameen, 2009; Santos et al., 2007</xref>). There are no standard treatments, although approaches usually include chemotherapy, multiple surgical excisions, and/or cryosurgery with liquid nitrogen. Furthermore, there is often a poor response to oral antifungal drugs, and most attempts at treatment have only a modest success rate (<xref rid="bib1 bib21" ref-type="bibr">Ameen, 2009; Santos et al., 2007</xref>).</p>
      <p>A number of melanized dematiaceous fungi have been associated with chromoblastomycosis, but the most common agent causing this disease is <italic>Fonsecaea pedrosoi</italic> (<xref rid="bib2" ref-type="bibr">Bonifaz et al., 2001</xref>). Little is known about this fungus, its cell wall structure, how it is recognized by the host, or the protective /nonprotective immune responses that are triggered upon infection. Host defense against experimental chromoblastomycosis has been shown to rely mainly on the ingestion and elimination of fungal cells by cells of the innate immune system, especially neutrophils and macrophages, but there is also some evidence supporting a requirement of CD4<sup>+</sup>, although not CD8<sup>+</sup>, T cell-mediated immune responses (<xref rid="bib1 bib21" ref-type="bibr">Ameen, 2009; Santos et al., 2007</xref>). Notable features of patients with chromoblastomycosis include increased IL-10 and low levels of IFN-γ (<xref rid="bib1 bib21" ref-type="bibr">Ameen, 2009; Santos et al., 2007</xref>).</p>
      <p>We were interested in understanding the reasons underlying the chronic nature of infection with <italic>F. pedrosoi</italic> and wanted to explore the possibility that the chronicity of this infection might stem from an inappropriate innate immune response. In this report, we show that <italic>F. pedrosoi</italic> is recognized by C-type lectin receptors (CLRs), but that there is a lack of sufficient costimulation of the Toll-like receptors (TLRs), and that this results in defective inflammatory responses. Excitingly, we could re-establish this costimulatory cytokine response by exogenous administration of TLR agonists, which could also be used to resolve the infection in vivo.</p>
    </sec>
    <sec id="sec2">
      <title>Results</title>
      <sec id="sec2.1">
        <title>Establishment and Characterization of a Murine Model of Chromoblastomycosis</title>
        <p>To explore the reasons underlying the chronicity of chromoblastomycosis, we made use of an established murine model (<xref rid="bib6" ref-type="bibr">Cardona-Castro and Agudelo-Flórez, 1999</xref>), where mice are infected intraperitoneally (i.p.) with <italic>F. pedrosoi</italic> conidia, following which the organism disseminates to the liver and spleen, where it persists for many weeks (<xref rid="fig1" ref-type="fig">Figure 1</xref>A). By comparison, infection with a pathogen causing an acute infection, such as <italic>Candida albicans</italic>, is cleared rapidly (<xref rid="bib24" ref-type="bibr">Tsoni et al., 2009</xref>) (dotted line in <xref rid="fig1" ref-type="fig">Figure 1</xref>A). Characterization of the spleens of the infected animals revealed high levels of IL-10 as well as low levels of TNF and IFN-γ, cytokine profiles similar to those described in infected humans (<xref rid="bib1 bib21" ref-type="bibr">Ameen, 2009; Santos et al., 2007</xref>) (<xref rid="fig1" ref-type="fig">Figure 1</xref>B).</p>
        <p>To determine whether IL-10 was contributing to the persistence of the infection in our mice, we compared fungal burdens and cytokine profiles in wild-type and IL-10-deficient animals 7 days after infection. This time point was chosen as it allowed us to examine primarily the innate response to this pathogen (see later). Unexpectedly, the lack of IL-10 only marginally reduced the fungal burdens in the organs of the infected animals and did not greatly influence the inflammatory responses to this pathogen, as determined by measuring the levels of TNF in the infected organs (<xref rid="fig1" ref-type="fig">Figures 1</xref>C and <xref rid="app2" ref-type="sec">S1</xref>). Thus, these results suggested that IL-10 was not a major factor involved in establishing the chronicity of infection with <italic>F. pedrosoi</italic>.</p>
      </sec>
      <sec id="sec2.2">
        <title><italic>F. pedrosoi</italic> Fails to Induce Inflammatory Responses from Macrophages</title>
        <p>We next explored the innate recognition of <italic>F. pedrosoi</italic> by characterizing its interactions with thioglycollate-elicited macrophages in vitro. We found that the conidia bound to macrophages in a dose-dependent fashion, yet surprisingly failed to stimulate the production of TNF, even at high multiplicities of infection (moi) (<xref rid="fig2" ref-type="fig">Figure 2</xref>A). In contrast, recognition of the fungal particle zymosan, which was included as a control in these experiments, induced a robust inflammatory response, as expected (<xref rid="bib5" ref-type="bibr">Brown et al., 2003</xref>).</p>
        <p>To explore the possibility that <italic>F. pedrosoi</italic> was actively suppressing leukocyte inflammatory responses, we examined the interaction of macrophages with heat-killed (HK) conidia. However, despite the heat treatment, macrophages still failed to respond to the conidia (<xref rid="fig2" ref-type="fig">Figure 2</xref>B). In addition, prolonged coculture for 20 hr with viable conidia, during which time the pathogen formed hyphae, similarly did not result in the induction of TNF (data not shown). The targeting of complement receptor 3 (CR3) is another suppressive mechanism of fungi (<xref rid="bib3" ref-type="bibr">Brandhorst et al., 2004</xref>); however, loss of CR3 did not restore TNF responses to <italic>F. pedrosoi</italic> conidia (<xref rid="fig2" ref-type="fig">Figure 2</xref>C). Thus, the lack of inflammatory responses to <italic>F. pedrosoi</italic> was due to a failure of innate recognition and not active suppression by the pathogen.</p>
      </sec>
      <sec id="sec2.3">
        <title>Inflammatory Responses to <italic>F. pedrosoi</italic> Can Be Reinstated by TLR Costimulation</title>
        <p>We have previously demonstrated that the recognition of fungal β-glucans by macrophages is not sufficient to induce inflammatory responses, in the absence of additional costimulation through MyD88-coupled TLRs (<xref rid="bib5 bib7 bib20" ref-type="bibr">Brown et al., 2003; Dennehy et al., 2008; Rosas et al., 2008</xref>). Thus, we next considered the possibility that the failure of <italic>F. pedrosoi</italic> conidia to induce inflammatory responses was due to a lack of PRR costimulation. We first determined whether β-glucans were exposed in <italic>F. pedrosoi</italic> and could demonstrate that both conidial and hyphal forms of this pathogen displayed these carbohydrates at the cell surface (<xref rid="fig2" ref-type="fig">Figure 2</xref>D). Interestingly, heat killing did not significantly alter the level of β-glucan exposure (<xref rid="app2" ref-type="sec">Figure S2</xref>A). Using transfected macrophages, we could also demonstrate that the β-glucan receptor Dectin-1 could directly mediate the binding of <italic>F. pedrosoi</italic> conidia to host cells (<xref rid="fig2" ref-type="fig">Figure 2</xref>E).</p>
        <p>We then explored the effect of TLR costimulation on macrophage inflammatory responses by making use of substimulatory doses of the TLR2 agonist Pam<sub>3</sub>CSK<sub>4</sub>, which we had previously shown to work synergistically with Dectin-1 (<xref rid="bib7" ref-type="bibr">Dennehy et al., 2008</xref>). Remarkably, while the addition of <italic>F. pedrosoi</italic> conidia to macrophages failed to induce significant levels of TNF, as we had observed before, costimulation with Pam<sub>3</sub>CSK<sub>4</sub> induced robust responses (<xref rid="fig2" ref-type="fig">Figure 2</xref>F). Similar results were also observed using human peripheral blood-derived macrophages and murine bone-marrow-derived dendritic cells (BMDCs) (<xref rid="fig2" ref-type="fig">Figure 2</xref>G). Furthermore, as we had previously demonstrated with purified β-glucan (<xref rid="bib7" ref-type="bibr">Dennehy et al., 2008</xref>), costimulation with <italic>F. pedrosoi</italic> could be achieved using multiple TLR agonists, including LPS (TLR4) and Imiquimod (TLR7) (<xref rid="fig2" ref-type="fig">Figures 2</xref>G and <xref rid="app2" ref-type="sec">S2</xref>B). It is notable that the stimulation of BMDCs with <italic>F. pedrosoi</italic> alone induced some TNF, which was expected, as stimulation of the Dectin-1/Syk signaling pathway in dendritic cells (DCs) is known to be sufficient for cytokine induction (<xref rid="bib8 bib19 bib20" ref-type="bibr">Dennehy et al., 2009; Rogers et al., 2005; Rosas et al., 2008</xref>).Thus, the inability of <italic>F. pedrosoi</italic> to induce robust inflammatory responses was due to a lack of costimulation of the TLR pathway.</p>
        <p>To confirm the role of Dectin-1 in these responses, we next assessed the costimulatory response in Dectin-1-deficient macrophages. As shown previously (<xref rid="bib7" ref-type="bibr">Dennehy et al., 2008</xref>), the costimulatory response to highly purified β-glucans was ablated in Dectin-1<sup>−/−</sup> cells. Unexpectedly, Dectin-1-deficient macrophages displayed no alterations in their ability to induce costimulatory responses to <italic>F. pedrosoi</italic> conidia (<xref rid="fig2" ref-type="fig">Figure 2</xref>F). Furthermore, we found that loss of Dectin-1 had no effect on the ability of primary macrophages to bind <italic>F. pedrosoi</italic> conidia (<xref rid="app2" ref-type="sec">Figure S2</xref>C), and characterization of Dectin-1<sup>−/−</sup> mice revealed only marginal effects on fungal burdens in the organs of the infected animals (<xref rid="app2" ref-type="sec">Figure S2</xref>D). Thus, Dectin-1 does not contribute to the costimulatory responses that were observed in vitro and plays only a minor role during infection in vivo.</p>
      </sec>
      <sec id="sec2.4">
        <title><italic>F. pedrosoi</italic>-TLR Costimulation Requires Mincle and Signaling through the Syk/CARD9 Pathway</title>
        <p>To determine the signaling pathways and receptors involved in mediating the costimulatory response, we next characterized BMDCs deficient in various signaling molecules. We first examined BMDCs deficient in MyD88 to confirm the involvement of this pathway and, as expected, found that the coaddition of <italic>F. pedrosoi</italic> and Pam<sub>3</sub>CSK<sub>4</sub> failed to induce a robust inflammatory response in these cells (<xref rid="fig3" ref-type="fig">Figure 3</xref>A). Interestingly, the response to <italic>F. pedrosoi</italic> alone was also partly attenuated, indicating some involvement of the MyD88 pathway in sensing of this pathogen by DCs. Indeed when examined further, we found that mice deficient in MyD88 had enhanced fungal burdens during infection (<xref rid="app2" ref-type="sec">Figure S3</xref>A). We next determined if the costimulatory response required signaling through Syk and CARD9, as we had shown for Dectin-1 (<xref rid="bib7" ref-type="bibr">Dennehy et al., 2008</xref>), and observed that BMDCs deficient in Syk (<xref rid="fig3" ref-type="fig">Figure 3</xref>B) or CARD9 (<xref rid="fig3" ref-type="fig">Figure 3</xref>C) failed to induce robust inflammatory responses in the presence of <italic>F. pedrosoi</italic> and Pam<sub>3</sub>CSK<sub>4</sub>. The responses to <italic>F. pedrosoi</italic> alone were also attenuated in these cells.</p>
        <p>To date, the only other Syk-coupled receptors that have been implicated in fungal recognition are the CLRs Mincle and Dectin-2, and both signal through the FcRγ chain (<xref rid="bib10" ref-type="bibr">Drummond et al., 2011</xref>). Hence, we examined the role of this signaling adaptor and found that the costimulatory response was lost in Fcγ<sup>−/−</sup> BMDCs (<xref rid="fig3" ref-type="fig">Figure 3</xref>D). We then explored the possibility of Dectin-2 involvement, by inhibiting this receptor with blocking monoclonal antibodies, but observed no effect on these responses (<xref rid="app2" ref-type="sec">Figure S3</xref>B). In contrast, we found that the costimulatory responses were completely ablated in Mincle<sup>−/−</sup> BMDCs and that this defect was specific for the recognition of <italic>F. pedrosoi</italic>, as Mincle<sup>−/−</sup> BMDCs retained normal responses to LPS (<xref rid="fig3" ref-type="fig">Figures 3</xref>E and <xref rid="app2" ref-type="sec">S3</xref>C). Thus, these results identify the Fcγ-coupled CLR Mincle as a major receptor involved in the innate recognition of <italic>F. pedrosoi</italic>. A model of the proposed costimulatory pathway is shown in <xref rid="fig3" ref-type="fig">Figure 3</xref>F.</p>
      </sec>
      <sec id="sec2.5">
        <title>TLR Costimulation Cures <italic>F. pedrosoi</italic> Infection</title>
        <p>The failure of <italic>F. pedrosoi</italic> to induce robust inflammatory responses provides a possible explanation for the persistence of this pathogen, so we investigated the possibility that artificial costimulation of the TLR pathway, to reinstate inflammatory responses, would help resolve the infection in vivo. We first determined if this was possible by administering <italic>F. pedrosoi</italic> i.p., with or without LPS, and monitoring TNF production in the peritoneal cavity after 3 hr. LPS was chosen for these and subsequent experiments, as the effects and dosage of this TLR agonist in vivo are well characterized and as we had shown it to be able to costimulate inflammatory responses to <italic>F. pedrosoi</italic> in vitro (<xref rid="bib7" ref-type="bibr">Dennehy et al., 2008</xref>) (see <xref rid="fig2" ref-type="fig">Figures 2</xref>G and <xref rid="app2" ref-type="sec">S2</xref>B). As shown in <xref rid="fig4" ref-type="fig">Figure 4</xref>A, the administration of either <italic>F. pedrosoi</italic> conidia or a low dose of LPS induced little TNF, but when added in combination, they induced a robust inflammatory response.</p>
        <p>To demonstrate an effect on fungal clearance, mice were infected with <italic>F. pedrosoi</italic> and the disease was allowed to establish for 3 days, following which a single low dose of LPS was administered either i.p. or i.v., and the infection in the organs was assessed after a further 4 days (<xref rid="fig4" ref-type="fig">Figure 4</xref>B). Remarkably, the administration of a single low dose of LPS, via either route, resulted in a near complete clearance of the pathogen from both the spleen and liver, in comparison to the untreated animals (<xref rid="fig4" ref-type="fig">Figures 4</xref>C and <xref rid="app2" ref-type="sec">S4</xref>A). Furthermore, as predicted from our in vitro analyses, the administration of LPS significantly increased the levels of TNF in the infected organs (<xref rid="fig4" ref-type="fig">Figures 4</xref>C and <xref rid="app2" ref-type="sec">S4</xref>A). This induction of TNF was critical for fungal clearance, since we found LPS to have no beneficial effect in mice deficient in this cytokine (<xref rid="fig4" ref-type="fig">Figures 4</xref>D and <xref rid="app2" ref-type="sec">S4</xref>B). In addition, similar effects of LPS on fungal burdens were observed in RAG2<sup>−/−</sup> mice (<xref rid="fig4" ref-type="fig">Figures 4</xref>E and <xref rid="app2" ref-type="sec">S4</xref>C).</p>
        <p>Our results suggest that the administration of TLR agonists may be a form of treatment for chromoblastomycosis in humans, ideally through the topical application of these agonists to infected skin. However, it is possible that TLR agonists would not be effective in treating subcutaneous infections. To explore this, we infected mice subcutaneously with <italic>F. pedrosoi</italic> and then treated some animals with topical applications of the FDA-approved agonist Imiquimod, which was also capable of inducing costimulatory activity in vitro (see <xref rid="fig2" ref-type="fig">Figure 2</xref>). Remarkably, we found that the topical application of Imiquimod significantly reduced fungal burdens in the skin at day 7 postinfection (<xref rid="fig4" ref-type="fig">Figure 4</xref>F). Similar reductions in fungal burdens were also obtained in these tissues following the i.p. administration of LPS on day 3 postinfection. Thus, we conclude that reinstating innate inflammatory responses to <italic>F. pedrosoi</italic> by artificial TLR costimulation in vivo can help resolve this normally persistent infection.</p>
      </sec>
    </sec>
    <sec id="sec3">
      <title>Discussion</title>
      <p>Very little is known about the immunology underlying chromoblastomycosis or the reasons for the chronicity of the disease. In this report we demonstrate that the chronic nature of this infection stems from inadequate innate recognition and the subsequent failure to mount protective inflammatory responses. This failure was not due to active suppression by <italic>F. pedrosoi</italic>, as inflammatory responses to HK organisms were similarly defective. Furthermore, this chronicity was not due to high levels of IL-10, as the level of infection was not greatly altered in mice deficient in this immunosuppressive cytokine. Although <italic>F. pedrosoi</italic> was recognized by leukocyte CLRs, particularly Mincle, we found that this recognition was not sufficient in and of itself to trigger protective inflammatory responses.</p>
      <p>These findings were reminiscent of β-glucan recognition by Dectin-1, which required costimulation of MyD88-coupled TLRs to induce robust inflammatory responses (<xref rid="bib7" ref-type="bibr">Dennehy et al., 2008</xref>). Indeed, we found that costimulation of leukocytes with purified TLR agonists induced robust inflammatory responses to <italic>F. pedrosoi</italic>, indicating that it was the lack of recognition by this PRR family that was responsible for the defective innate responses. Like Dectin-1, the costimulatory response required signaling via the Syk-CARD9 pathway, but was triggered by the FcRγ-coupled CLR Mincle. We could demonstrate this definitively by showing that the costimulatory responses to this organism were lost in cells deficient in any of these signaling components. While it is likely that Mincle is recognizing a mannose-based cell wall component (<xref rid="bib26" ref-type="bibr">Yamasaki et al., 2009</xref>), the identity of the ligand is unclear. It should also be noted that unlike macrophages, the recognition of <italic>F. pedrosoi</italic> did induce some response in DCs, even in the absence of TLR costimulation. For other Syk-dependent responses, such as those triggered through Dectin-1, these cellular differences have been linked to the effects of cytokines, such as the GM-CSF used to generate the DCs and the differential usage of CARD9, but the underlying reasons are still not fully understood (<xref rid="bib10" ref-type="bibr">Drummond et al., 2011</xref>). Nonetheless, as for Dectin-1, TLR costimulation induced robust inflammatory responses to <italic>F. pedrosoi</italic> in both cell types.</p>
      <p>The immunostimulatory components within the cell walls of many fungi are thought to be shielded, possibly providing an explanation for the failure of <italic>F. pedrosoi</italic> to induce protective responses. However, the lack of response to dead organisms indicates that this is unlikely, as heat killing is thought to disrupt the cell wall architecture and expose underlying PAMPs (<xref rid="bib18" ref-type="bibr">Robinson et al., 2009</xref>). Although this suggests that <italic>F. pedrosoi</italic> lacks sufficient levels of exposed TLR ligands to stimulate robust responses, the partial ablation of TNF production in the MyD88<sup>−/−</sup> DCs does indicate the presence of some ligands for these receptors. What the nature of these ligands may be is unclear, as the architecture and composition of the cell wall of <italic>F. pedrosoi</italic> is largely unknown. Furthermore, the significant increase in fungal burdens in the MyD88-deficient mice might also suggest some contribution of TLR recognition to the control of this pathogen, but the interpretation of these results are complicated by the role of MyD88 in IL-1 receptor signaling and the importance of IL-1 signaling in antifungal immunity.</p>
      <p>The failure of leukocytes to induce robust inflammatory responses to <italic>F. pedrosoi</italic> led us to test the possibility that inducing these responses, through the exogenous administration of TLR agonists, could help resolve the infection in vivo. Indeed, using a murine model of systemic infection, we found that the administration of LPS, either i.v. or i.p., significantly reduced fungal burdens in infected organs. This increased fungal clearance was due to the enhanced inflammatory responses triggered by the exogenous costimulation of the TLRs, as LPS failed to have an effect in TNF<sup>−/−</sup> mice. However, LPS has also been shown to induce Mincle expression in vitro (<xref rid="bib16" ref-type="bibr">Matsumoto et al., 1999</xref>), therefore raising the possibility of an indirect contribution of this TLR agonist in host responses.</p>
      <p>While the systemic mouse model of chromoblastomycosis is not an accurate representation of the human subcutaneous infection, it is thought to be the best model for studying the chronic nature of this disease (<xref rid="bib6" ref-type="bibr">Cardona-Castro and Agudelo-Flórez, 1999</xref>). Indeed, the systemic infection is chronic in mice, and the pathogen persists for many weeks in the organs of untreated animals. Importantly, the ability of artificial TLR costimulation to restore inflammatory responses and induce rapid fungal clearance, particularly in RAG-deficient mice, clearly demonstrates that the persistence of this fungal pathogen is primarily due to defective innate recognition. However, chronic infection with <italic>F. pedrosoi</italic> also leads to dysregulated adaptive immunity (<xref rid="bib17" ref-type="bibr">Mazo Fávero Gimenes et al., 2005</xref>), which was not addressed here, and it would be interesting to examine the effect of TLR agonist treatment on the development of these responses during the infection.</p>
      <p>Excitingly, these results suggest that the exogenous administration of TLR agonists could be used to treat human patients. Although the majority of our studies were performed using disseminated infections, we could demonstrate that a similar approach was also feasible in a subcutaneous infection model. While this approach requires further optimization, we found that the topical application of Imiquimod significantly reduced fungal burdens in the infected tissues. Our in vitro data also suggest that such an approach may work in humans, as human macrophages, like their mouse counterparts, failed to induce robust inflammatory responses to <italic>F. pedrosoi</italic> in the absence of artificial TLR costimulation.</p>
      <p>In conclusion, we have shown that the persistence of infection with <italic>F. pedrosoi</italic> is due to a failure in innate recognition, stemming from a lack of TLR costimulation. It is tempting to speculate that defective PRR costimulation may underlie the development of other chronic infections and that enhancement of inflammatory responses may be responsible for the anti-infective activities reported for many immunostimulants, such as β-glucan. Our results also highlight the importance of coordinated PRR signaling and demonstrate how exogenously applied PRR agonists could be used to treat these types of diseases. For chromoblastomycosis in humans, this might simply involve the topical application of appropriate TLR ligands, such as Imiquimod.</p>
    </sec>
    <sec sec-type="methods" id="sec4">
      <title>Experimental Procedures</title>
      <sec id="sec4.1">
        <title>Animals</title>
        <p>Male or female 8- to 14-week-old 129Sv, 129Sv Dectin-1<sup>−/−</sup> (<xref rid="bib23" ref-type="bibr">Taylor et al., 2007</xref>), BALB/C, BALB/C IL-10<sup>−/−</sup> (<xref rid="bib9" ref-type="bibr">Dewals et al., 2010</xref>), C57BL/6, C57BL/6 RAG2<sup>−/−</sup> (<xref rid="bib9" ref-type="bibr">Dewals et al., 2010</xref>), C57BL/6 TNF<sup>−/−</sup> (<xref rid="bib15" ref-type="bibr">Marino et al., 1997</xref>), and C57BL/6 Myd88<sup>−/−</sup> (<xref rid="bib11" ref-type="bibr">Fremond et al., 2004</xref>) mice were obtained from the specific pathogen-free facility of the University of Cape Town. All animal experimentation was performed using groups of 5–10 animals, repeated at least once, and conformed to institutional guidelines for animal care and welfare.</p>
      </sec>
      <sec id="sec4.2">
        <title><italic>F. pedrosoi</italic> Growth Conditions and Fluorescent Labeling</title>
        <p><italic>F. pedrosoi</italic> ATCC 46428 was streaked onto potato dextrose agar or Sabouraud agar plates for isolation of individual colonies for 12 days. Colonies were cultured in a shaking incubator for 72 hr at 30°C in potato broth for in vitro and in vivo assays. The conidia were filtered to remove hyphae and washed with PBS before use (live conidia) or were heat killed by boiling for 30 min. For fluorescence labeling, washed live or HK conidia were labeled with Rhodamine Green-X (Invitrogen) (200 μg/ml) for 30 min at 25°C, followed by extensive washing. To detect surface-exposed β-glucans, washed live or HK <italic>F. pedrosoi</italic> cells were stained with soluble Fc-Dectin-1(<xref rid="bib12" ref-type="bibr">Graham et al., 2006</xref>) or Fc-CLEC9A (<xref rid="bib14" ref-type="bibr">Huysamen et al., 2008</xref>) chimeric proteins (5 μg/ml), as described previously (<xref rid="bib12" ref-type="bibr">Graham et al., 2006</xref>). In some experiments, soluble β-glucan (100 μg/ml) was mixed with Fc-Dectin-1 for 30 min prior to staining.</p>
      </sec>
      <sec id="sec4.3">
        <title>Cells and In Vitro Fungal Stimulations</title>
        <p>DCs were generated from Syk<sup>−/−</sup> fetal livers, as described (<xref rid="bib19" ref-type="bibr">Rogers et al., 2005</xref>), or from the bone marrow of CARD9<sup>−/−</sup> (<xref rid="bib13" ref-type="bibr">Gross et al., 2009</xref>), FcRγ<sup>−/−</sup> (<xref rid="bib22" ref-type="bibr">Takai et al., 1994</xref>), Mincle<sup>−/−</sup> (<xref rid="bib26" ref-type="bibr">Yamasaki et al., 2009</xref>), MyD88, and C57BL/6 mice, using standard protocols. Human monocyte-derived macrophages and thioglycollate-elicited macrophages were generated as described previously (<xref rid="bib7 bib25" ref-type="bibr">Dennehy et al., 2008; Willment et al., 2003</xref>). Macrophages and BMDCs were plated the night before use in 24-well plates at a density of 2.5 × 10<sup>5</sup> cells per well in RPMI medium with 10% heat-inactivated FCS. The RAW264.7 macrophages expressing Dectin-1 (<xref rid="bib4" ref-type="bibr">Brown et al., 2002</xref>) and control cells were plated at 2.5 × 10<sup>5</sup> cells per well in medium containing 0.4 mg/ml G418 (Invitrogen).</p>
        <p>For the in vitro binding and cytokine assays, unlabeled or Rhodamine Green-X-labeled live or HK <italic>F. pedrosoi</italic> were added to the cells, as indicated, and incubated for 30 min at 37°C. In some experiments, the following compounds were also added alone or in combination, as indicated: unlabeled or FITC-labeled zymosan (25 particles per cell) (Invitrogen), purified β-glucan particles (100 μg/ml) (<xref rid="bib7" ref-type="bibr">Dennehy et al., 2008</xref>), Pam<sub>3</sub>CSK<sub>4</sub> (10 ng/ml) (Invivogen), LPS (1 ng/ml) (Sigma), and Imiquimod (1 μg/ml) (Invivogen). Unbound particles were removed by washing. The medium was replaced, and the cells were cultured for a further 3 hr for analysis of TNF by ELISA (BD Biosciences). Cytokine stimulations were not influenced by the presence or absence of a fluorescent label on the fungal particles (data not shown). After incubation, supernatants were stored at −80°C until use, cells were lysed in 3% (volume/volume) Triton X-100, and fluorescence was measured with a Titertek Fluoroskan II (Labsystems).</p>
      </sec>
      <sec id="sec4.4">
        <title>In Vivo Models</title>
        <p>For in vivo infections, mice were infected with 2 × 10<sup>6</sup> conidia of <italic>F. pedrosoi</italic> i.p. In some experiments, LPS (10 ng) (Sigma) was also administered to mice i.p. or i.v., 3 days after infection with <italic>F. pedrosoi</italic>. At appropriate time points after infection, as indicated in the text, the animals were sacrificed, and colony-forming units were determined in disaggregated whole livers and spleens by serial dilution onto Sabouraud agar plates. Organ cytokine levels were determined by ELISA (BD Biosciences). To measure peritoneal inflammation, mice were injected i.p. with 2 × 10<sup>6</sup> live <italic>F. pedrosoi</italic> and/or LPS (10 ng/ml) and were killed after 3 hr. TNF was measured in peritoneal lavage fluid by ELISA (BD Biosciences). For infection of the footpad, mice were subcutaneously injected with 1 × 10<sup>7</sup> <italic>F. pedrosoi</italic> conidia, and then 5% Imiquimod cream (Aldara, Graceway Phamaceuticals) was topically applied daily to the site of infection, where indicated. In other mice, 100 ng of LPS was administered i.p. at day 3 after infection. All mice were sacrificed at day 7, and colony-forming units were determined in disaggregated footpads by serial dilution onto Sabouraud agar plates.</p>
      </sec>
      <sec id="sec4.5">
        <title>Statistics</title>
        <p>Student's t test was used for the analysis of two groups. Results were considered statistically significant with p values of ≤ 0.05.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bib1">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ameen</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Chromoblastomycosis: clinical presentation and management</article-title>
          <source>Clin. Exp. Dermatol.</source>
          <volume>34</volume>
          <year>2009</year>
          <fpage>849</fpage>
          <lpage>854</lpage>
          <pub-id pub-id-type="pmid">19575735</pub-id>
        </element-citation>
      </ref>
      <ref id="bib2">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bonifaz</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Carrasco-Gerard</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Saúl</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Chromoblastomycosis: clinical and mycologic experience of 51 cases</article-title>
          <source>Mycoses</source>
          <volume>44</volume>
          <year>2001</year>
          <fpage>1</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">11398635</pub-id>
        </element-citation>
      </ref>
      <ref id="bib3">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brandhorst</surname>
              <given-names>T.T.</given-names>
            </name>
            <name>
              <surname>Wüthrich</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Finkel-Jimenez</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Warner</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>B.S.</given-names>
            </name>
          </person-group>
          <article-title>Exploiting type 3 complement receptor for TNF-alpha suppression, immune evasion, and progressive pulmonary fungal infection</article-title>
          <source>J. Immunol.</source>
          <volume>173</volume>
          <year>2004</year>
          <fpage>7444</fpage>
          <lpage>7453</lpage>
          <pub-id pub-id-type="pmid">15585870</pub-id>
        </element-citation>
      </ref>
      <ref id="bib4">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>G.D.</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Reid</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Willment</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>D.L.</given-names>
            </name>
            <name>
              <surname>Martinez-Pomares</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>S.Y.</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Dectin-1 is a major beta-glucan receptor on macrophages</article-title>
          <source>J. Exp. Med.</source>
          <volume>196</volume>
          <year>2002</year>
          <fpage>407</fpage>
          <lpage>412</lpage>
          <pub-id pub-id-type="pmid">12163569</pub-id>
        </element-citation>
      </ref>
      <ref id="bib5">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>G.D.</given-names>
            </name>
            <name>
              <surname>Herre</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>D.L.</given-names>
            </name>
            <name>
              <surname>Willment</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Marshall</surname>
              <given-names>A.S.J.</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Dectin-1 mediates the biological effects of beta-glucans</article-title>
          <source>J. Exp. Med.</source>
          <volume>197</volume>
          <year>2003</year>
          <fpage>1119</fpage>
          <lpage>1124</lpage>
          <pub-id pub-id-type="pmid">12719478</pub-id>
        </element-citation>
      </ref>
      <ref id="bib6">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cardona-Castro</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Agudelo-Flórez</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Development of a chronic chromoblastomycosis model in immunocompetent mice</article-title>
          <source>Med. Mycol.</source>
          <volume>37</volume>
          <year>1999</year>
          <fpage>81</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="pmid">10361262</pub-id>
        </element-citation>
      </ref>
      <ref id="bib7">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dennehy</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Ferwerda</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Faro-Trindade</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Pyz</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Willment</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Kerrigan</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Tsoni</surname>
              <given-names>S.V.</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Meyer-Wentrup</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Syk kinase is required for collaborative cytokine production induced through Dectin-1 and Toll-like receptors</article-title>
          <source>Eur. J. Immunol.</source>
          <volume>38</volume>
          <year>2008</year>
          <fpage>500</fpage>
          <lpage>506</lpage>
          <pub-id pub-id-type="pmid">18200499</pub-id>
        </element-citation>
      </ref>
      <ref id="bib8">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dennehy</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Willment</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>D.L.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>G.D.</given-names>
            </name>
          </person-group>
          <article-title>Reciprocal regulation of IL-23 and IL-12 following co-activation of Dectin-1 and TLR signaling pathways</article-title>
          <source>Eur. J. Immunol.</source>
          <volume>39</volume>
          <year>2009</year>
          <fpage>1379</fpage>
          <lpage>1386</lpage>
          <pub-id pub-id-type="pmid">19291703</pub-id>
        </element-citation>
      </ref>
      <ref id="bib9">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dewals</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Hoving</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Horsnell</surname>
              <given-names>W.G.</given-names>
            </name>
            <name>
              <surname>Brombacher</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Control of Schistosoma mansoni egg-induced inflammation by IL-4-responsive CD4(+)CD25(-)CD103(+)Foxp3(-) cells is IL-10-dependent</article-title>
          <source>Eur. J. Immunol.</source>
          <volume>40</volume>
          <year>2010</year>
          <fpage>2837</fpage>
          <lpage>2847</lpage>
          <pub-id pub-id-type="pmid">20821727</pub-id>
        </element-citation>
      </ref>
      <ref id="bib10">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Drummond</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Saijo</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Iwakura</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>G.D.</given-names>
            </name>
          </person-group>
          <article-title>The role of Syk/CARD9 coupled C-type lectins in antifungal immunity</article-title>
          <source>Eur. J. Immunol.</source>
          <volume>41</volume>
          <year>2011</year>
          <fpage>276</fpage>
          <lpage>281</lpage>
          <pub-id pub-id-type="pmid">21267996</pub-id>
        </element-citation>
      </ref>
      <ref id="bib11">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fremond</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Yeremeev</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Nicolle</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Jacobs</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Quesniaux</surname>
              <given-names>V.F.</given-names>
            </name>
            <name>
              <surname>Ryffel</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88</article-title>
          <source>J. Clin. Invest.</source>
          <volume>114</volume>
          <year>2004</year>
          <fpage>1790</fpage>
          <lpage>1799</lpage>
          <pub-id pub-id-type="pmid">15599404</pub-id>
        </element-citation>
      </ref>
      <ref id="bib12">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Graham</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Tsoni</surname>
              <given-names>S.V.</given-names>
            </name>
            <name>
              <surname>Willment</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>D.L.</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Dennehy</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>G.D.</given-names>
            </name>
          </person-group>
          <article-title>Soluble Dectin-1 as a tool to detect beta-glucans</article-title>
          <source>J. Immunol. Methods</source>
          <volume>314</volume>
          <year>2006</year>
          <fpage>164</fpage>
          <lpage>169</lpage>
          <pub-id pub-id-type="pmid">16844139</pub-id>
        </element-citation>
      </ref>
      <ref id="bib13">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gross</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Poeck</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Bscheider</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Dostert</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Hannesschläger</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Endres</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hartmann</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Tardivel</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Schweighoffer</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Tybulewicz</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
          <article-title>Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence</article-title>
          <source>Nature</source>
          <volume>459</volume>
          <year>2009</year>
          <fpage>433</fpage>
          <lpage>436</lpage>
          <pub-id pub-id-type="pmid">19339971</pub-id>
        </element-citation>
      </ref>
      <ref id="bib14">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huysamen</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Willment</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Dennehy</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>G.D.</given-names>
            </name>
          </person-group>
          <article-title>CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3+ dendritic cells and a subset of monocytes</article-title>
          <source>J. Biol. Chem.</source>
          <volume>283</volume>
          <year>2008</year>
          <fpage>16693</fpage>
          <lpage>16701</lpage>
          <pub-id pub-id-type="pmid">18408006</pub-id>
        </element-citation>
      </ref>
      <ref id="bib15">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marino</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>Dunn</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Grail</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Inglese</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Noguchi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Richards</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Jungbluth</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Wada</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Williamson</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Characterization of tumor necrosis factor-deficient mice</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <volume>94</volume>
          <year>1997</year>
          <fpage>8093</fpage>
          <lpage>8098</lpage>
          <pub-id pub-id-type="pmid">9223320</pub-id>
        </element-citation>
      </ref>
      <ref id="bib16">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matsumoto</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kaisho</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Sanjo</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Copeland</surname>
              <given-names>N.G.</given-names>
            </name>
            <name>
              <surname>Gilbert</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Jenkins</surname>
              <given-names>N.A.</given-names>
            </name>
            <name>
              <surname>Akira</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>A novel LPS-inducible C-type lectin is a transcriptional target of NF-IL6 in macrophages</article-title>
          <source>J. Immunol.</source>
          <volume>163</volume>
          <year>1999</year>
          <fpage>5039</fpage>
          <lpage>5048</lpage>
          <pub-id pub-id-type="pmid">10528209</pub-id>
        </element-citation>
      </ref>
      <ref id="bib17">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mazo Fávero Gimenes</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Da Glória de Souza</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>K.S.</given-names>
            </name>
            <name>
              <surname>Marques</surname>
              <given-names>S.G.</given-names>
            </name>
            <name>
              <surname>Gonçalves</surname>
              <given-names>A.G.</given-names>
            </name>
            <name>
              <surname>Vagner de Castro Lima Santos</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Pedroso e Silva</surname>
              <given-names>Cde.M.</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>S.R.</given-names>
            </name>
          </person-group>
          <article-title>Cytokines and lymphocyte proliferation in patients with different clinical forms of chromoblastomycosis</article-title>
          <source>Microbes Infect.</source>
          <volume>7</volume>
          <year>2005</year>
          <fpage>708</fpage>
          <lpage>713</lpage>
          <pub-id pub-id-type="pmid">15848277</pub-id>
        </element-citation>
      </ref>
      <ref id="bib18">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robinson</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Osorio</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Rosas</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Freitas</surname>
              <given-names>R.P.</given-names>
            </name>
            <name>
              <surname>Schweighoffer</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Gross</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Verbeek</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Ruland</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Tybulewicz</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>G.D.</given-names>
            </name>
          </person-group>
          <article-title>Dectin-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection</article-title>
          <source>J. Exp. Med.</source>
          <volume>206</volume>
          <year>2009</year>
          <fpage>2037</fpage>
          <lpage>2051</lpage>
          <pub-id pub-id-type="pmid">19703985</pub-id>
        </element-citation>
      </ref>
      <ref id="bib19">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rogers</surname>
              <given-names>N.C.</given-names>
            </name>
            <name>
              <surname>Slack</surname>
              <given-names>E.C.</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Nolte</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Schulz</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Schweighoffer</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>D.L.</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tybulewicz</surname>
              <given-names>V.L.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>G.D.</given-names>
            </name>
            <name>
              <surname>Reis e Sousa</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins</article-title>
          <source>Immunity</source>
          <volume>22</volume>
          <year>2005</year>
          <fpage>507</fpage>
          <lpage>517</lpage>
          <pub-id pub-id-type="pmid">15845454</pub-id>
        </element-citation>
      </ref>
      <ref id="bib20">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rosas</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Liddiard</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kimberg</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Faro-Trindade</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>McDonald</surname>
              <given-names>J.U.</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>D.L.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>G.D.</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>P.R.</given-names>
            </name>
          </person-group>
          <article-title>The induction of inflammation by dectin-1 in vivo is dependent on myeloid cell programming and the progression of phagocytosis</article-title>
          <source>J. Immunol.</source>
          <volume>181</volume>
          <year>2008</year>
          <fpage>3549</fpage>
          <lpage>3557</lpage>
          <pub-id pub-id-type="pmid">18714028</pub-id>
        </element-citation>
      </ref>
      <ref id="bib21">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Santos</surname>
              <given-names>A.L.</given-names>
            </name>
            <name>
              <surname>Palmeira</surname>
              <given-names>V.F.</given-names>
            </name>
            <name>
              <surname>Rozental</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kneipp</surname>
              <given-names>L.F.</given-names>
            </name>
            <name>
              <surname>Nimrichter</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Alviano</surname>
              <given-names>D.S.</given-names>
            </name>
            <name>
              <surname>Rodrigues</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Alviano</surname>
              <given-names>C.S.</given-names>
            </name>
          </person-group>
          <article-title>Biology and pathogenesis of Fonsecaea pedrosoi, the major etiologic agent of chromoblastomycosis</article-title>
          <source>FEMS Microbiol. Rev.</source>
          <volume>31</volume>
          <year>2007</year>
          <fpage>570</fpage>
          <lpage>591</lpage>
          <pub-id pub-id-type="pmid">17645522</pub-id>
        </element-citation>
      </ref>
      <ref id="bib22">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takai</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sylvestre</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Clynes</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Ravetch</surname>
              <given-names>J.V.</given-names>
            </name>
          </person-group>
          <article-title>FcR gamma chain deletion results in pleiotrophic effector cell defects</article-title>
          <source>Cell</source>
          <volume>76</volume>
          <year>1994</year>
          <fpage>519</fpage>
          <lpage>529</lpage>
          <pub-id pub-id-type="pmid">8313472</pub-id>
        </element-citation>
      </ref>
      <ref id="bib23">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taylor</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Tsoni</surname>
              <given-names>S.V.</given-names>
            </name>
            <name>
              <surname>Willment</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Dennehy</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Rosas</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Findon</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Haynes</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Steele</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Botto</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>G.D.</given-names>
            </name>
          </person-group>
          <article-title>Dectin-1 is required for beta-glucan recognition and control of fungal infection</article-title>
          <source>Nat. Immunol.</source>
          <volume>8</volume>
          <year>2007</year>
          <fpage>31</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="pmid">17159984</pub-id>
        </element-citation>
      </ref>
      <ref id="bib24">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsoni</surname>
              <given-names>S.V.</given-names>
            </name>
            <name>
              <surname>Kerrigan</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Marakalala</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Srinivasan</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Duffield</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Botto</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Steele</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>G.D.</given-names>
            </name>
          </person-group>
          <article-title>Complement C3 plays an essential role in the control of opportunistic fungal infections</article-title>
          <source>Infect. Immun.</source>
          <volume>77</volume>
          <year>2009</year>
          <fpage>3679</fpage>
          <lpage>3685</lpage>
          <pub-id pub-id-type="pmid">19581397</pub-id>
        </element-citation>
      </ref>
      <ref id="bib25">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Willment</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>H.H.</given-names>
            </name>
            <name>
              <surname>Reid</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>D.L.</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>S.Y.</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>G.D.</given-names>
            </name>
          </person-group>
          <article-title>Dectin-1 expression and function are enhanced on alternatively activated and GM-CSF-treated macrophages and are negatively regulated by IL-10, dexamethasone, and lipopolysaccharide</article-title>
          <source>J. Immunol.</source>
          <volume>171</volume>
          <year>2003</year>
          <fpage>4569</fpage>
          <lpage>4573</lpage>
          <pub-id pub-id-type="pmid">14568930</pub-id>
        </element-citation>
      </ref>
      <ref id="bib26">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamasaki</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Takeuchi</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Matsuzawa</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Ishikawa</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Sakuma</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Tateno</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Uno</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Hirabayashi</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Mikami</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>C-type lectin Mincle is an activating receptor for pathogenic fungus, Malassezia</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <volume>106</volume>
          <year>2009</year>
          <fpage>1897</fpage>
          <lpage>1902</lpage>
          <pub-id pub-id-type="pmid">19171887</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <sec id="app2" sec-type="supplementary-material">
      <title>Supplemental Information</title>
      <p>
        <supplementary-material content-type="local-data" id="mmc1">
          <caption>
            <title>Document S1. Four Figures</title>
          </caption>
          <media xlink:href="mmc1.pdf" mimetype="application" mime-subtype="pdf"/>
        </supplementary-material>
      </p>
    </sec>
    <ack>
      <title>Acknowledgments</title>
      <p>We thank the staff of our animal facilities for the care of the animals used in these studies. This work was funded by Wellcome Trust.</p>
    </ack>
  </back>
  <floats-group>
    <fig id="fig1">
      <label>Figure 1</label>
      <caption>
        <p>Establishment of a Murine Model of Infection with <italic>F. pedrosoi</italic></p>
        <p>(A) Fungal burdens in the spleen and liver (black lines) at various time points, as indicated, following i.p. infection with <italic>F. pedrosoi</italic> conidia. Shown for comparison is the clearance rate of a similar dose of <italic>C. albicans</italic> (dotted line) (<xref rid="bib24" ref-type="bibr">Tsoni et al., 2009</xref>).</p>
        <p>(B) Characterization of the levels of IL-10, IFN-γ, and TNF from infected spleens.</p>
        <p>(C) Characterization of fungal burdens and cytokine levels in the spleens of wild-type (WT; black symbols) versus IL-10<sup>−/−</sup> (white symbols) mice at day 7 postinfection. See also <xref rid="app2" ref-type="sec">Figure S1</xref>. Values shown are the mean ± SEM of two pooled experiments, except for (C), which is mean ± SD. <sup>∗</sup>p &lt; 0.05.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <fig id="fig2">
      <label>Figure 2</label>
      <caption>
        <p>The Response of Thioglycollate-Elicited Peritoneal Macrophages to <italic>F. pedrosoi</italic> Is Defective, but Can Be Restored Following Exogenous TLR Costimulation</p>
        <p>(A) Binding of <italic>F. pedrosoi</italic> and measurement of TNF responses in macrophage culture supernatants, 3 hr after stimulation with conidia (moi 5:1 and 50:1).</p>
        <p>(B) Binding of live and heat-killed (HK) <italic>F. pedrosoi</italic> and measurement of TNF responses in macrophage culture supernatants, 3 hr after stimulation with conidia (MOI 5:1).</p>
        <p>(C) Binding of <italic>F. pedrosoi</italic> and measurement of TNF responses in wild-type (WT; black bars) versus CR3<sup>−/−</sup> (white bars) macrophage culture supernatants, 3 hr after stimulation with conidia (MOI 5:1 and 50:1).</p>
        <p>(D) Confocal image showing staining of live <italic>F. pedrosoi</italic> conidia and hyphae with soluble Fc-Dectin-1 or Fc-CLEC9A chimeric proteins. See also <xref rid="app2" ref-type="sec">Figure S2</xref>A.</p>
        <p>(E) Binding of <italic>F. pedrosoi</italic> conidia (MOI 1:1 and 1:10) to RAW264.7 cells transduced with Dectin-1 (black bars) or vector control (white bars).</p>
        <p>(F) Costimulation of wild-type (WT; black bars) or Dectin-1<sup>−/−</sup> (white bars) thioglycollate-elicited macrophages with Pam<sub>3</sub>CSK<sub>4</sub>, β-glucan particles, or <italic>F. pedrosoi</italic> (MOI 5:1 and 25:1), as indicated. See also <xref rid="app2" ref-type="sec">Figures S2</xref>C and S2D.</p>
        <p>(G) Costimulation of human monocyte-derived macrophages (MΦ) or murine bone-marrow-derived dendritic cells (BMDCs) with <italic>F. pedrosoi</italic> (MOI 5:1), Pam<sub>3</sub>CSK<sub>4</sub> (10 ng/ml), LPS (1 ng/ml), or Imiquimod (1μg/ml), as indicated. See also <xref rid="app2" ref-type="sec">Figure S2</xref>B. In some experiments, zymosan (zy; 25 particles per cell) was included as a positive control. Values shown are the mean ± SD, and the data are representative of at least two independent experiments, except for the human MΦ, which are mean ± SEM of pooled data from three donors. <sup>∗</sup>p &lt; 0.05.</p>
      </caption>
      <graphic xlink:href="gr2"/>
    </fig>
    <fig id="fig3">
      <label>Figure 3</label>
      <caption>
        <p>Characterization of the Components Involved in the TLR/<italic>F. pedrosoi</italic> Costimulatory Response</p>
        <p>(A–E) Measurement of TNF levels in BMDC supernatants following a 3 hr stimulation with Pam<sub>3</sub>CSK<sub>4</sub> or <italic>F. pedrosoi</italic> (MOI 5:1), as indicated. Responses were measured in wild-type (WT; black bars) cells versus BMDCs deficient (white bars) in MyD88 (A), Syk (B), CARD9 (C), FcRγ (D), or Mincle (E). See also <xref rid="app2" ref-type="sec">Figure S3</xref>. Values shown are the mean ± SD, and the data are representative of at least two independent experiments.</p>
        <p>(F) Cartoon representation of the costimulatory signaling pathway induced by <italic>F. pedrosoi</italic> and exogenous TLR costimulation.</p>
      </caption>
      <graphic xlink:href="gr3"/>
    </fig>
    <fig id="fig4">
      <label>Figure 4</label>
      <caption>
        <p>Curing <italic>F. pedrosoi</italic> Infection In Vivo by Exogenous Administration of TLR Agonists</p>
        <p>(A) TNF in the peritoneum of mice 3 hr after the i.p. administration of <italic>F. pedrosoi</italic> or LPS (10 ng), as indicated. Values shown are the mean ± SEM of two pooled experiments.</p>
        <p>(B) Schematic diagram of the experimental approach, showing i.p. infection with <italic>F. pedrosoi,</italic> followed by i.p. or i.v. injection on day 3 with a single low dose of LPS (10 ng). The mice were sacrificed and analyzed 4 days later (day 7).</p>
        <p>(C) Fungal burdens and TNF levels in the spleens of infected mice with or without LPS treatment, as indicated. See also <xref rid="app2" ref-type="sec">Figure S4</xref>A. Values shown are the mean ± SD. <sup>∗</sup>p &lt; 0.05.</p>
        <p>(D) Fungal burdens in the spleens of infected wild-type (black circles) or TNF<sup>−/−</sup> (white circles) mice with or without LPS treatment, as indicated. See also <xref rid="app2" ref-type="sec">Figure S4</xref>B.</p>
        <p>(E) Fungal burdens in the spleens of infected wild-type (black circles) or RAG2<sup>−/−</sup> (white circles) mice with or without LPS treatment, as indicated. See also <xref rid="app2" ref-type="sec">Figure S4</xref>C.</p>
        <p>(F) Fungal burdens in the footpads at day 7 of untreated infected mice (black circles), i.p. LPS-treated mice (gray circles), or mice treated daily with a topical application of Imiquimod (IMQ) (white circles).</p>
      </caption>
      <graphic xlink:href="gr4"/>
    </fig>
  </floats-group>
</article>